Quantcast

Tuberculosis Drug Shows Promise Against Latent Bacteria

September 15, 2008

Tuberculosis drug shows promise against latent bacteria

WASHINGTON, Sept. 12 (Xinhua) — A new study has shown that an investigational drug R207910, currently in clinical trials against multi-drug resistant tuberculosis strains, is quite effective at killing latent bacteria, a report said on Friday.

This revelation suggests that R207910 may lead to improved and shortened treatments for this globally prevalent disease, researchers from Johnson & Johnson reported in the Sept. 12 issue of Journal of Biological Chemistry.

Despite numerous treatment advances, tuberculosis (TB) remains a serious disease — fueled by co-infection of HIV patients, the rise of drug-resistant strains, and the ability of Mycobacterium tuberculosis to become dormant and linger in the lungs.

People can be infected, asymptotically, with latent TB and is at risk of developing active TB disease during their life time.

The research team tested R207910 on dormant M. tuberculosis in three different laboratory models of latency. R207910 targets a protein essential for making cellular energy (ATP) in actively replicating TB.

They reasoned that even dormant bacteria, which are essentially physiologically “turned off,” still need to produce small quantities of ATP to survive. As such, a block in ATP synthesis might be vital for killing dormant bacteria.

This reasoning proved to be correct and R207190 was able to kill dormant bacteria by greater than 95 percent whereas current drugs like isoniazid had no effect.

Surprisingly, they found that R207910 is slightly more effective in killing dormant bacteria as compared to actively replicating ones, a unique spin as all known TB drugs are more effective on replicating bugs. Researchers hope to validate these results clinically, and note that ATP synthase should be looked at as a drug target for other persistent bacterial infections.

(c) 2008 Xinhua News Agency – CEIS. Provided by ProQuest LLC. All rights Reserved.




comments powered by Disqus